Researchers at The University of Texas at Austin have developed an experimental drug that tricks aggressive cancer cells into consuming more sugar than usual while simultaneously blocking their backup fat metabolism. According to a study published in Nature Chemical Biology, the compound successfully treated an aggressive form of melanoma in mice by attacking both cellular energy sources at once, putting the cancer cells under fatal metabolic stress.
How the Experimental Two-Part Drug Targets Cancer Metabolism
Cancer cells typically rely on a high-volume sugar supply to fuel rapid growth, prompting researchers to traditionally study ways of cutting off that supply. However, the UT Austin team deployed a completely different mechanism by designing a molecule that forces cancer cells into overdrive regarding sugar consumption. According to Xiaolu (Lulu) Lim Ang Cambronne, associate professor of molecular biosciences at UT and co-corresponding author, the technology functions like a two-headed dragon that simultaneously weakens another part of the cell.
The drug features a two-part design developed by Xiaoding Jiang, a postdoctoral fellow in the Hsu Lab. The targeting agent—a molecule named XJ-4-85—acts on an enzyme called PFKL to accelerate glycolysis inside cancer cells. Once bound, it releases a secondary payload that targets an enzyme called CPT2, which normally breaks down fatty acids for energy. By disrupting both energy pathways simultaneously, the compound shuts down cancer growth.
Did you know? Unlike traditional antibody-drug conjugates (ADCs) that are large and limited to surface proteins, this new class of compounds—termed electrophile-drug conjugates (EDCs)—are smaller, easier to manufacture, and capable of targeting proteins located inside cancer cells, according to associate professor of chemistry Ken Hsu.
Lab Results Across Multiple Human Cancer Cell Lines
In laboratory experiments detailed in the Nature Chemical Biology study, the compound proved effective against several types of human cancer cells. According to the research team, these include melanoma, leukemia, breast cancer, lung cancer, liver cancer, and neuroblastoma. In mice treated for melanoma, the majority of cancer cells died while non-cancerous cells experienced significantly less impact.
Despite these promising laboratory results, the research remains in its early stages. According to the study authors, extensive additional laboratory testing is required before clinical trials involving human patients can begin. Beyond oncology, the research team notes that electrophile-drug conjugates hold broader potential for treating other types of diseases in the future.
Frequently Asked Questions
How does the new drug kill cancer cells?
The experimental drug uses a two-part mechanism: it forces cancer cells to accelerate their consumption of sugar while simultaneously blocking CPT2, an enzyme responsible for breaking down fatty acids, cutting off the cell’s dual energy sources.
How is this different from antibody-drug conjugates (ADCs)?
While ADCs use large antibodies to target surface proteins on cancer cells, the new chemical compounds are smaller and capable of penetrating cells to target internal proteins, while also offering simpler manufacturing processes according to UT Austin researchers.
Has the drug been tested in humans?
No. The research has currently only been demonstrated in lab experiments involving human cancer cell lines and in mice with melanoma. Further laboratory testing is required before human clinical trials.
What funding sources supported the research?
The study received financial support from the National Institutes of Health, the National Institute of General Medical Sciences, the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Washington Beckman Cryo-EM Center, West Virginia University’s Visual Sciences CoBRE program, the Melanoma Research Alliance, the Mark Foundation for Cancer Research, The Welch Foundation, and Tito’s Handmade Vodka.
What are your thoughts on this dual-pronged metabolic approach to cancer research? Join the discussion by leaving a comment below, or explore our science archive for more breakthrough coverage.
Keep reading